In today’s briefing:
- Bukwang Pharmaceutical (003000 KS): Open Innovation Approach on Track to Launch New Drugs
Bukwang Pharmaceutical (003000 KS): Open Innovation Approach on Track to Launch New Drugs
- Bukwang Pharmaceutical (003000 KS) is developing innovative new drug candidates in partnership with pharmaceutical and bio-venture companies in Korea and abroad.
- Antipsychotic lurasidone (brand name: Latuda), in-licensed from Sumitomo Pharma is the lead candidate of Bukwang’s innovative drug pipeline. Lurasidone will be launched in 3–4 years in Korea.
- Recently, Bukwang announced positive phase 1 trial for SOL-804 for the treatment of prostate cancer, in-licensed from Solural Pharma. SOL-804 has an addressable market opportunity of KRW23 trillion in 2027.
Before it’s here, it’s on Smartkarma
